Bavarian Nordic A/S is a fully integrated biotechnology company specializing in the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. Founded in 1994 and headquartered in Hellerup, Denmark, the company leverages its proprietary Modified Vaccinia Ankara (MVA-BN) platform to create safe and effective prophylactic and therapeutic vaccine candidates. Bavarian Nordic’s core mission is to protect global public health by addressing unmet medical needs through innovative vaccine solutions.
The company’s flagship product is JYNNEOS (also known as Imvamune or Imvanex), an MVA-BN–based vaccine approved for prevention of smallpox and monkeypox. JYNNEOS has received regulatory approval in the United States, European Union and other markets, and is used by government agencies and health authorities to bolster biodefense preparedness and to respond to emerging viral threats. In addition to its commercial portfolio, Bavarian Nordic maintains a robust pipeline of clinical-stage candidates targeting respiratory and vector-borne diseases, as well as cancer immunotherapies designed to stimulate the immune system against tumor antigens.
Bavarian Nordic operates state-of-the-art manufacturing facilities in Denmark and the United States, enabling end-to-end vaccine production from cell culture to fill-finish. The company has established long-term supply agreements and strategic partnerships with governmental agencies, non-profit organizations and multinational pharmaceutical firms. These collaborations support both routine immunization programs and emergency response initiatives, and position Bavarian Nordic as a reliable supplier of critical vaccines to markets in North America, Europe and select emerging economies.
Under the leadership of President and Chief Executive Officer Paul A. Chaplin, Bavarian Nordic emphasizes scientific excellence and operational scalability. The company’s executive team combines expertise in vaccinology, regulatory affairs and global supply chain management to advance its portfolio and expand its market reach. Committed to transparency and quality, Bavarian Nordic adheres to stringent regulatory standards and regularly engages with stakeholders to anticipate evolving public health needs.